新検索ページはこちら
ログイン
お問い合わせ
（旧版）前立腺癌診療ガイドライン 2006年版
書誌情報
第1章 疫学
参考文献
| 1） | Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64. |
| 2） | がんの統計‘03: 悪性新生物年齢調整罹患率，主要部位別・年次別（昭和50年～平成10年）:http://www.ncc.go.jp/jp/statistics/2003/data08.pdf :accessed on July 27, 2004. |
| 3） | 大野ゆう子，中村 隆，大島 明，他:日本のがん罹患の将来推計．がん・統計白書-罹患/死亡/予後－2004（大島 明，黒石哲生，田島和雄，編）．篠原出版新社; 2004．p.201-17． |
| 4） | がんの統計‘03:悪性新生物年齢調整死亡率，主要部位別・年次別（昭和25年～平成13年）:http://www.ncc.go.jp/jp/statistics/2003/data05.pdf :accessed on July 27, 2004. |
| 5） | 黒石哲生，広瀬かおる，田島和雄，他:日本のがん死亡の将来予測．がん・統計白書－罹患/死亡/予後－2004（大島明，黒石哲生，田島和雄，編）．篠原出版新社;2004．p.219-34． |
| 6） | Yatani R, Chigusa I, Akazaki K, et al. Geographic pathology of latent prostatic carcinoma. Int J Cancer. 1982;29:611-6. |
| 7） | Etzioni R, Cha R, Feuer EJ, et al. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol. 1998;148:775-85. |
| 8） | 白石泰三，他:前立腺ラテント癌．前立腺癌診療マニュアル，前立腺研究財団，金原出版;1995．p.13-24． |
| 9） | 渡辺 泱:前立腺癌の自然史．前立腺癌診療マニュアル，前立腺研究財団，金原出版，1995．p.1-12． |
| 10） | 伊藤一人，山本 巧，大井 勝，他:前立腺集団検診受診者における国際前立腺症状スコアー（I-PSS）の傾向とQOL indexとの関係．泌尿器外科．2001;14:868-71． |
| 11） | 福多史昌，舛森直哉，田中吉則，他:下部尿路症状を主訴とする受診症例における前立腺癌発見率．臨床泌尿器科．2005;59:133-8． |
| 12） | Lepor H, Owens RS, Rogenes V, et al. Detection of prostate cancer in males with prostatism. Prostate. 1994;25:132-40. |
| 13） | Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate. 1990;17:337-47. |
| 14） | Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993;85:1571-9. |
| 15） | 中田誠司，他:日本及び世界における前立腺癌死亡と食摂取様式の相関分析．癌の臨床．1994;40:831-6． |
| 16） | Hebert JR, Hurley TG, Olendzki BC, et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality:a cross-national study. J Natl Cancer Inst. 1998;90:1637-47. |
| 17） | Eichholzer M, Stahelin HB, Ludin E, et al. Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate cancer:seventeen-year follow-up of the prospective Basel study. Prostate. 1999;38:189-98. |
| 18） | Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation:results of a double-blind cancer prevention trial. Br J Urol. 1998;81:730-4. |
| 19） | Hartman TJ, Albanes D, Pietinen P, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev. 1998;7:335-40. |
| 20） | Smith RA, Cokkinides V, Eyre HJ, et al. American Cancer Society guidelines for the early detection of cancer, 2004. CA Cancer J Clin. 2004;54:41-52. |
| 21） | Prostate-specific antigen（PSA）best practice policy. American Urological Association（AUA）. Oncology（Williston Park）. 2000;14:267-72, 277-8, 280 passim. |
| 22） | Recommendations and Rationale. Screening for Prostate Cancer:U. S. Preventive Services Task Force（USPSTF）: http://www.ahrq.gov/clinic/3rduspstf/prostatescr/prostaterr.htm :accessed on November 12, 2004. |
| 23） | Harris R, Lohr KN.:Screening for prostate cancer:an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:917-29. |
| 24） | Roberts RO, Bergstralh EJ, Katusic SK, et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol. 1999;161:529-33. |
| 25） | Meyer F, Moore L, Bairati I, et al. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol. 1999;161:1189-91. |
| 26） | Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58:417-24. |
| 27） | Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian（PLCO）Cancer Screening Trial. Control Clin Trials. 2000:21（6 Suppl）:273S-309S. |
| 28） | Schröder FH, Denis LJ, Roobol M, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2003;92 suppl 2:1-13. |
| 29） | 財団法人 前立腺研究財団，前立腺検診協議会:人間ドック健診における前立腺検査調査（1989年～1999年）・前立腺集団検診全国集計（1986年～1999年）．泌尿器外科．2003;16:1023-38． |
| 30） | Kubota Y, Ito K, Imai K, et al. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate. 2002;50:262-9. |
| 31） | Ito K, Yamamoto T, Suzuki K, et al. The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0ng/ml or less. J Urol. 2004;171:656-60. |
| 32） | Ito K, Yamamoto T, Ohi M, et al. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0ng/ml or less. Prostate. 2003;57:8-13. |
| 33） | Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan:2000 report from the Japanese Urological Association. Int J Urol. 2005;12:46-61. |
